|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||27.25 - 27.54|
|52 Week Range||20.45 - 30.80|
|PE Ratio (TTM)||-356.36|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.88|
LAWRENCE, Mass., Oct. 18, 2017 /PRNewswire/ -- NxStage Medical, Inc. (NXTM), a leading medical technology company focused on advancing renal care, today announced Dawn Meade as the national winner of the third annual Nurse Hero Award. The Nurse Hero Award was designed to recognize the important role home hemodialysis (HHD) nurses play in helping patients to receive access to this life-changing dialysis therapy. "NxStage congratulates Dawn and all of the other nominees on being recognized by their patients and peers for their commitment to providing extraordinary patient care," said NxStage President, Joe Turk.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to NxStage Medical, Inc. Here are 5 ETFs with the largest exposure to NXTM-US. Comparing the performance and risk of NxStage Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis NxStage Medical, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of NxStage Medical, Inc. – Cantel Medical Corp. (CMD-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 96.22 million, Net Earnings of USD -2.09 ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for NxStage Medical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
ATLANTA , Oct. 2, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced the appointment of Jeffrey ...
NEW YORK , Sept. 10, 2017 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...
The latest regulatory go-ahead is likely to lend NxStage (NXTM) a competitive edge and expand its patient base with solid access to the clinical benefits associated with home hemodialysis.
LAWRENCE, Mass., Aug. 28, 2017 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that the U.S. Food and Drug Administration (FDA) has cleared its System One for solo home hemodialysis, without a care partner, during waking hours. Since receiving its first clearance for home hemodialysis from the FDA in 2005 and the first and only home nocturnal hemodialysis clearance in 2014, the NxStage System One has provided over 14 million treatments to thousands of patients in their homes around the world, during the day and at night. However, certain patients have not had access to this therapy option due to the fact that the System One's indication has required that a care partner be present when a patient performs home hemodialysis.
LAWRENCE, Mass., Aug. 24, 2017 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that the NxStage® System One™ is now used in nine of the top ten nephrology hospitals in the United States, and fifteen of the top twenty, as identified by U.S. News & World Report.1 The System One simplifies care in acute care settings and allows staff to deliver the prescribed renal replacement therapy via a variety of modalities to critically ill patients. The System One offers multiple features designed to simplify therapies in hospitals. In addition, the System One's range of flow rates allows hospital staff to individualize therapy based on the condition of the patient.
IN THE NEWS Benzinga President Donald Trump asked Americans to support his decision to put more U.S. troops in the rugged terrain of Afghanistan, perhaps staking his imperiled presidency on bringing peace ...
The following statement is being issued by Levi & Korsinsky, LLP:
NEW ORLEANS , Aug. 14, 2017 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...
The latest development will lend NxStage Medical (NXTM) a competitive edge in the hemodialysis dialysis market. The company will leverage on its System One platform for treating patients with ESRD.
BALA CYNWYD, PA / ACCESSWIRE / August 11, 2017 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of NxStage Medical, Inc. ("NxStage" ...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives NxStage Medical, Inc. a score of 31. Our analysis is based on comparing NxStage Medical, Inc. with the following peers – Cantel Medical Corp., Rockwell Medical, Inc., Fresenius Medical Care AG & Co. KGaA Sponsored ADR, Baxter International Inc., C. R. Bard, Inc., Nephros, Inc., Boston Scientific ... Read more (Read more...)
LAWRENCE, Mass., Aug. 11, 2017 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that its NxStage Kidney Care subsidiary is partnering with Dialyze Direct, a leader in the area of geriatric dialysis and an innovative provider of staff-assisted home hemodialysis to patients in SNFs, to better support the needs of Ohio's skilled nursing facility (SNF) population with end stage renal disease (ESRD). Dialyze Direct will be implementing its unique model of care specifically designed for geriatric SNF patients to provide on-site dialysis using the NxStage System One. On-site dialysis performed at a SNF removes organizational and operational challenges for dialysis centers and care facilities, while reducing or eliminating the stress placed on patients during transportation. The portability of the NxStage System One makes it possible to provide SNF patients with access to on-site dialysis, including more frequent hemodialysis, versus transporting them, often by ambulance, to an off-site dialysis center three times per week.
Fresenius Medical's (FMS) latest development is expected to fortify the company's foothold in the Home dialysis market, particularly in the renal care space.